- Home
- BPMC
as 01-21-2025 4:00pm EST
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 6.7B | IPO Year: | 2015 |
| Target Price: | $122.72 | AVG Volume (30 days): | 789.4K |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $72.24 - $121.90 | Next Earning Date: | 02-13-2025 |
| Revenue: | $434,415,000 | Revenue Growth: | 100.93% |
| Revenue Growth (this year): | 108.09% | Revenue Growth (next year): | 39.34% |
Stock Insider Trading Activity of Blueprint Medicines Corporation (BPMC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | BPMC | Director | Jan 13 '25 | Sell | $102.28 | 5,000 | $511,400.00 | 157,557 | |
| Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | Jan 13 '25 | Sell | $100.00 | 2,250 | $225,000.00 | 14,967 | |
| Albers Jeffrey W. | BPMC | Director | Dec 19 '24 | Sell | $90.10 | 15,000 | $1,346,615.40 | 157,557 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | Dec 18 '24 | Sell | $96.19 | 2,274 | $218,098.08 | 69,383 | |
| Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | Dec 12 '24 | Sell | $93.44 | 1,819 | $169,635.81 | 14,967 | |
| Haviland Kate | BPMC | CHIEF EXECUTIVE OFFICER | Nov 29 '24 | Sell | $96.63 | 2,353 | $227,304.36 | 151,031 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | Nov 27 '24 | Sell | $95.10 | 2,274 | $216,257.40 | 69,383 | |
| COATS LONNEL | BPMC | Director | Nov 20 '24 | Sell | $94.31 | 19,824 | $1,869,657.63 | 17,566 | |
| Albers Jeffrey W. | BPMC | Director | Nov 7 '24 | Sell | $102.00 | 5,000 | $510,000.00 | 157,557 |
Latest Blueprint Medicines Corporation News
BPMC Breaking Stock News: Dive into BPMC Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines
Zacks
7 days ago
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
Zacks
7 days ago
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
Zacks
8 days ago
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?
MT Newswires
8 days ago
Blueprint Medicines Expects Systemic Mastocytosis Franchise to Generate $4 Billion by 2030 -- Shares Up
GuruFocus.com
8 days ago
Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor
PR Newswire
9 days ago
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
Simply Wall St.
13 days ago
High Growth Tech Stocks to Watch in January 2025
Compare BPMC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BPMC Blueprint Medicines Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.